ArticleTherapeutic advances in gastroenterology2026
Using artificial intelligence to identify characteristics associated with clinical and economic outcomes in MASH (FOCUS-MASH).
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heterogeneity in the disease characteristics of metabolic dysfunction-associated steatohepatitis (MASH) complicates efforts to identify individuals with high unmet need. Objective: We used artificial intelligence (AI) phenotyping to identify factors associated with rapid fibrosis progression, long-term clinical outcomes, and high healthcare costs. Design: In this retrospective cohort study (January 1, 2013-September 1, 2022), patients with a MASH diagnosis, a Fibrosis-4 index score within 90 days of first MASH diagnosis, and no other liver diseases were identified in a United States electronic medical records and claims dataset. Methods: Using machine learning, characteristics, including diagnoses, procedures, and medications, were grouped into phenotypic signals, which were iteratively refined and evaluated for strength of association with each outcome. Differences between subgroups in the proportions of patients with specific phenotypic signals were calculated. Results: In total, 14,707 patients were included in at least one analysis. Rapid fibrosis progression ( Conclusion: This study demonstrates the application of AI phenotyping to multidimensional real-world data. This approach could support new methods for proactively identifying patients in clinical practice who require closer monitoring and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.